- Home
- BBU vs ANIP Comparison
BBU vs ANIP Comparison
Compare BBU & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBU
- ANIP
- Stock Information
- Founded
- BBU 2016
- ANIP 2001
- Country
- BBU Bermuda
- ANIP United States
- Employees
- BBU N/A
- ANIP N/A
- Industry
- BBU Engineering & Construction
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- BBU Consumer Discretionary
- ANIP Health Care
- Exchange
- BBU Nasdaq
- ANIP Nasdaq
- Market Cap
- BBU 2.4B
- ANIP 2.0B
- IPO Year
- BBU N/A
- ANIP N/A
- Fundamental
- Price
- BBU $27.10
- ANIP $97.71
- Analyst Decision
- BBU Buy
- ANIP Strong Buy
- Analyst Count
- BBU 5
- ANIP 9
- Target Price
- BBU $31.80
- ANIP $86.00
- AVG Volume (30 Days)
- BBU 31.5K
- ANIP 475.8K
- Earning Date
- BBU 11-07-2025
- ANIP 11-07-2025
- Dividend Yield
- BBU 0.92%
- ANIP N/A
- EPS Growth
- BBU N/A
- ANIP N/A
- EPS
- BBU N/A
- ANIP N/A
- Revenue
- BBU $30,103,000,000.00
- ANIP $747,399,000.00
- Revenue This Year
- BBU N/A
- ANIP $39.32
- Revenue Next Year
- BBU $5.85
- ANIP $9.62
- P/E Ratio
- BBU N/A
- ANIP N/A
- Revenue Growth
- BBU N/A
- ANIP 38.68
- 52 Week Low
- BBU $18.63
- ANIP $52.50
- 52 Week High
- BBU $28.28
- ANIP $99.50
- Technical
- Relative Strength Index (RSI)
- BBU 52.54
- ANIP 75.51
- Support Level
- BBU $26.46
- ANIP $96.50
- Resistance Level
- BBU $28.10
- ANIP $99.50
- Average True Range (ATR)
- BBU 0.89
- ANIP 2.17
- MACD
- BBU -0.07
- ANIP -0.36
- Stochastic Oscillator
- BBU 40.15
- ANIP 81.77
About BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.